<DOC>
	<DOCNO>NCT00060424</DOCNO>
	<brief_summary>This clinical trial study well give fludarabine phosphate together total-body irradiation ( TBI ) donor peripheral blood stem cell transplant work treat patient chronic lymphocytic leukemia small lymphocytic leukemia . Giving low dos chemotherapy , fludarabine phosphate , TBI donor peripheral blood stem cell transplant help stop growth cancer cell . Giving chemotherapy peripheral blood stem cell transplant also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Phosphate Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant Treating Patients With Chronic Lymphocytic Leukemia Small Lymphocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether nonmyeloablative allogeneic hematopoietic stem cell transplantation ( HSCT ) matched-related donor improve probability survival 18 month treatment fludarabine ( fludarabine phosphate ) -refractory , fludarabine phosphate , cyclophosphamide , rituximab ( FCR ) -failed , del 17p chronic lymphocytic leukemia ( CLL ) beyond observed historical control ( 30 % ) . SECONDARY OBJECTIVES : I . To assess rate relapse allogeneic HSCT use nonmyeloablative conditioning patient fludarabine-refractory , FCR-failed , del 17p CLL compare historical data autologous HSCT . II . To estimate incidence grade 2-4 acute graft-versus-host disease ( GVHD ) chronic GVHD patient CLL treat low-dose TBI , fludarabine , peripheral blood stem cell ( PBSC ) infusion immunosuppression cyclosporine mycophenolate mofetil . III . To characterize rate type infection regimen . IV . To estimate rate transplant-related mortality first 200 day . OUTLINE : NONMYELOABLATIVE CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) day -4 -2 TBI day 0 . TRANSPLANT : Patients undergo allogeneic peripheral blood stem cell transplant day 0 . GVHD PROPHYLAXIS : Patients receive cyclosporine orally ( PO ) every 12 hour day -3 180 taper begin day 56 mycophenolate mofetil PO every 12 hour day 0-27 . After completion study treatment , patient follow 12 18 month annually 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , T-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients CLL ( small lymphocytic lymphoma ) diagnosis CLL progress prolymphocytic leukemia ( PLL ) , Tcell CLL PLL Patients BCell CLL PLL least one follow : Failed meet National Cancer Institute ( NCI ) Working Group criteria complete partial response therapy regimen contain fludarabine ( another nucleoside analog , e.g . cladribine [ 2CDA ] , pentostatin ) experience disease relapse within 12 month complete therapy regimen contain fludarabine ( another nucleoside analog ) Failed FCR combination chemotherapy time point Had de novo acquire `` 17p deletion '' cytogenetic abnormality ; patient receive induction chemotherapy could transplant first ( 1st ) complete response ( CR ) Patient suitable human leukocyte antigen ( HLA ) match related donor willing undergo leukapheresis initially collection PBSC subsequently collection peripheral blood mononuclear cell ( PBMC ) filgrastim ( GCSF ) mobilization willing donate stem cell DONOR : Related donor HLA phenotypically genotypically identical allele level HLAA , B , C , DRB1 , DQB1 DONOR : Donor must consent GCSF administration leukapheresis DONOR : Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) Infection human immunodeficiency virus ( HIV ) , human Tlymphotropic virus ( HTLV ) 1 , HTLV2 Active central nervous system ( CNS ) involvement CLL Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence Fertile men woman unwilling use contraceptive technique 12 month follow treatment Pregnant breastfeed woman Karnofsky score = &lt; 70 Fungal infection radiological progression receipt amphotericin B active triazole great 1 month Cytotoxic agents `` cytoreduction '' ( exception imatinib mesylate [ Gleevec ] , cytokine therapy , hydroxyurea , chlorambucil Rituxan ) within three week initiation condition Active bacterial fungal infection unresponsive medical therapy Cardiovascular : cardiac ejection fraction &lt; 40 % ; patient poorly control hypertension despite multiple antihypertensive Pulmonary : diffusing capacity carbon monoxide ( DLCO ) &lt; 40 % , total lung capacity ( TLC ) &lt; 40 % , forced expiratory volume one second ( FEV1 ) &lt; 40 % and/or require continuous supplementary oxygen , severe deficit pulmonary function test define pulmonary consultant service Liver function abnormality : patient clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , bridge fibrosis , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3mg/dL , symptomatic biliary disease DONOR : Age &lt; 12 year DONOR : Identical twin DONOR : Pregnancy DONOR : Infection HIV DONOR : Inability achieve adequate venous access DONOR : Known allergy filgrastim ( GCSF ) DONOR : Current serious systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>